Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis

PLoS Negl Trop Dis. 2020 Mar 26;14(3):e0008125. doi: 10.1371/journal.pntd.0008125. eCollection 2020 Mar.

Abstract

Background: The disturbance of host metabolic pathways by Leishmania parasites has crucial consequences for the activation status of immune cells and the outcome of infection. Glutamine has been described as an immunomodulatory amino acid, yet its role during Leishmania infection is still unknown.

Methods: We performed transcriptomics in uninfected and L. donovani-infected macrophages 6 hours post-infection. Glutamine quantification by HPLC was assessed in the supernatant of macrophages throughout the infection course. For experimental L. donovani infections, mice were infected with 1.0 x 108 stationary L. donovani promastigotes. Glutaminase (GLS) chemical inhibition was performed using BPTES and glutamine was administered throughout infection. For combined therapy experiment, a daily administration of miltefosine and glutamine was performed by oral gavage. Parasite burden was determined using a Taqman-based assay. Immune cell phenotyping and cytotoxicity were performed in splenic cells using flow cytometry.

Findings: We show that glutamine is essential for the control of L. donovani infection. Transcriptomic analysis of L. donovani-infected macrophages demonstrated an upregulation of genes involved in glutamine metabolism. Pharmacological inhibition of glutaminolysis significantly increased the susceptibility to infection, accompanied by an increased recruitment of anti-inflammatory myeloid cells and impaired T cell responses. Remarkably, the supplementation of glutamine to mice infected with L. donovani during miltefosine treatment potentiates parasite clearance through the development of a more effective anti-Leishmania adaptive immune response.

Conclusions: Our data indicates that dietary glutamine supplementation may act as a promising adjuvant for the treatment of visceral leishmaniasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Dietary Supplements*
  • Disease Models, Animal
  • Female
  • Glutamine / administration & dosage*
  • Humans
  • Immunologic Factors / administration & dosage*
  • Leishmaniasis, Visceral / therapy*
  • Macrophages / immunology
  • Male
  • Mice, Inbred C57BL
  • Parasite Load
  • Phosphorylcholine / administration & dosage
  • Phosphorylcholine / analogs & derivatives*
  • T-Lymphocyte Subsets / immunology
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Immunologic Factors
  • Glutamine
  • Phosphorylcholine
  • miltefosine

Grants and funding

This work was supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) (NORTE-01-0145-FEDER-000013) and the Fundação para a Ciência e Tecnologia (FCT) (contracts PD/BDE/127830/2016 to CF, SFRH/BD/120127/2016 to IM, SFRH/BD/120371/2016 to AMB, IF/00474/2014 to NSO, IF/01390/2014 to ET, CEECIND/03628/2017 to AC, CEECIND/04600/2017 to CC and IF/00021/2014 to RS), and Infect-Era Net (project INLEISH). JE also thanks the Canada Research Chair program for financial assistance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.